International Journal of Radiation Oncology, Biology, Physics 1993: Vol 25 Index

6 Pages·1993·1.8 MB·English

AUTHOR INDEX
Volume 25, 1993
Abner, A., 765 Cairncross, J. G., 877 Dewhirst, M. W., 269, 289, 481, 841 Gibbs Jr., F. A., 117
Adams, J., 339 Cardenosa, G., 439 Dickson, D. R., 733 Gioioso, D., 243
Ahmad, K., 193 Cashman, J. R., 67 Dilhuydy, J. M., 113 Girinsky, T., 3, 153, 871
Ahmad, N. R., 923 Cassisi, N. J., 619, 689 Dinges, S., 259 Glatstein, E., 445, 567
Akl, A. M., 623 Caudry, M., 907 Dinshaw, K. A., 926 Gleave, E. N., 379
Alberti, W. E., 753, 881 Causse, N., 907 Divoux, S., 881 Gliisenkamp, K.-H., 465
Albrink, F., 657 Cervek, J., 777 Dodge, R. K., 289, 841 Goitein, M., 135
Alexander III, E., 859 Chan, A., 791 Doggett, R. L. S., 399 Gospodarowicz, M., 623
Allal, A. S., 113 Chan, H., 215 Doherty, M., 215 Gould, R. G., 345
Allalunis-Turner, J., 243 Chan, P. H., 67 Donaldson, S. S., 565 Greenberg, M., 215
Allen, P. S., 695 Chan, S.,359 Donohue, J. H., 647 Grigsby, P. W., 399, 733, 895
Althof, V. G. M., 529 Chaney, E. L., 123 Doppke, K. P., 345 Gross, J. F., 481
Ang, K. K., 459 Chang, C. H., 209 Dougal, M., 23 Grudziak, A., 639
Angyalfi, S., 215 Chassagne, D., 405 Dougherty, J., 821 Guiney, M. J., 235
Ardiet, J. M., 513 Chavaudra, N., 3 Drake, J., 215 Gulenchyn, K. Y., 805
Armstrong, J. G., 17 Chen, G. T. Y., 359 Drzymala, R. E., 709 Gunderson, L. L., 647
Arterbery, V. E., 661 Cheng, E., 171 Dubray, B. M., 9 Guo, W.-Y., 315
Asano, K., 29 Chi, V. L., 123 Dubray, B., 3 Guthoff, R., 277
Asbell, S. O., 209, 783 Choy, D., 505 Gutin, P. H., 67
Asselain, B., 9 Chu, W., 325, 345 Earle, J. D., 921
Atkinson, J. C., 41 Chui, C. S., 161 Edmonson, J. H., 647 Haie-Meder, C., 405, 419
Austin, J. P., 439 Chumbley, L., 277 Edwards, J., 269 Hall, E. J., 381
Awan, A., 359 Clegg, S. T., 289 Eisbruch, A., 733 Halperin, E. C., 877
Coghe, M., 517 Eisenberg, B., 885 Halpern, H., 359
Ball, D., 599 Cohen, A. M., 821 Engin, K., 87 Hammond, E., 783
Barnett, R. B., 835 Coia, L., 131 Enker, W. E., 821 Hanks, G. E., 377, 391, 885
Barricks, M. E., 379 Cole, J. W., 445 Erlich, L. E., 805 Hansen, J. L., 79
Bastin, K. T., 703 Come, S. E., 765 Harder, D., 881
Bataini, J.-P., 9 Constine, L. S., 193 Fass, D. E., 17 Hareyama, M., 29
Bates, E. H., 431 Cook, J. M., 269 Faucher, A., 113 Harris, J. R., 765
Battista, J. J., 835 Cooper, B., 849 Fein, D. A., 605 Harrison, L. B., 17
Beatty, B. G., 473 Cosset, J. M., 3, 419, 871 Feng, Y., 459 Hayakawa, Y., 49, 499
Beatty, J. D., 473 Coughlin, C., 783 Fertil, B., 3 Hayat, M., 419
Beck-Bornholdt, H.-P., 154, 277 Crennan, E., 599 Fieck, J. M., 647 Hazuka, M. B., 339
Becker, L., 215 Creutzberg, C. L., 529 Fischbach, J., 193 Heaney, J., 783
Bécouarn, Y., 113 Cromartie, R., 333 Fisher, B. J., 677, 877 Hefner, L. V., 345
Behar, R. A., 771 Crook, J., 805 Fisher, R. J., 431 Heidorn, D. B., 629
Bernier, J., 9 Cufer, T., 777 Flamant, F., 419 Hendrick, B., 215
Berry, M., 215 Culbert, H., 359 Flickinger, J. C., 227, 557 Henk, J. M., 815
Bessell, E. M., 815 Cullip, T. J., 123 Floyd, K. L., 639 Henry-Amar, M., 871
Bissett, R., 623 Cumberlin, R., 745 Foote, R. L., 379 Herbert, S. H., 885
Bleehen, N., 243 Cummings, B. J., 613, 669 Fox, P. C., 41 Hercbergs, A., 283
Blivin, J. L., 841 Curran Jr., W. J., 193, 885 Fox, S., 895 Hermann, K.-P., 881
Bloch, P., 171 Frankel, J., 821 Hiraoka, T., 499
Boggs, S. S., 639 Dachowski, L., 445 Fraser, S. M., 79 Ho, C. M., 505
Bornstein, B. A., 79, 765 Daly, S. E., 835 Friauf, W. S., 445 Ho, J.-T., 251
Brahme, A., 373 Danjoux, C., 613 Fuchs, H., 123 Hodson, I., 613
Brenner, D. J., 381 Davis, R. L., 67 Fuks, Z., 161, 661 Hoerth, E., 829
Briot, E., 419 De Beukeleer, M., 517 Fukumoto, S., 49 Hoffman, H., 215
Brizel, D. M., 269 Deen, D. F., 251 Hoffman, J. P., 885
Brock, W. A., 147 DeLaney, T. F., 445 Galvin, J. M., 171, 181 Hogan, M., 885
Brunin, F., 9 De Laroche, G., 513 Gaspar, L. E., 677, 877 Holland, J., 299
Buchler, D. A., 525 Demeaux, H., 907 Gazeau, N., 3 Hong, K. E., 805
Buchsbaum, D. J., 629 De Neve, W., 517 Gehring, M., 309 Hooper, N., 67
Budach, V., 259 Deore, S. M., 926 Gelwan, L. A., 79 Hoover, S. V., 929
Budach, W., 243, 259 De Roover, P., 517 George, S. L., 289, 841 Hopewell, J. W., 927
Buechler, D., 117 Desgrez, A., 871 Gerard, J. P., 513 Hoppe, R. T., 771
Buncic, R., 215 Deutsch, M., 639 Gerbaulet, A., 405, 419 Horning, S. J., 771
Buras, R. R., 473 Deutsch, S., 929 Gerbi, B. G., 345 Hoshina, M., 35
XII
Hoshino, T., 251 Lawrence, T. S., 629 Michel, G., 419 Prosnitz, L. R., 841
Hsu, R., 481 Leavitt, D. D., 117 Michelson, S., 283 Purdy, J. A., 709, 895
Huckstep, R. L., 431 LeBer, D. V., 877 Million, R. R., 147, 425, 605, 619,
Hughes, P., 235 Lee, W. R., 683 683, 689 Quaranto, L., 283
Huizenga, H., 529 Leeper, D. B., 87 Minsky, B. D., 821
Humphreys, R., 215 Leibel, S. A., 161 Miralbell, R., 353 Rajewsky, M. F., 465
Hunt, J. W., 849 Leibrock, L. G., 325 Mistretta, C., 309 Ramsay, J., 243
Huyser-Wierenga, D., 695 Leigh, B. R., 801 Mlika-Cabanne, N., 419 Rawlinson, E., 613
Leith, J. T., 283 Moeller, J. H., 117 Recaldini, L., 907
Ibbott, G. S., 339 Leopold, K. A., 289, 841 Mohiuddin, M., 193, 209, 923 Recht, A., 765
Inada, T., 49, 491, 499 Leung, S., 413 Montbarbon, X., 513 Redgate, E. S., 639
Levendag, P. C., 529 Morin, R. L., 345 Reeves, M. A., 325
Jahde, E., 465 Levin, A., 309 Morita, K., 29 Reid, R., 805
Jaulerry, C., 9 Levin, K. J., 67 Moylan, D. J., 87 Richaud, P., 113
Jenkin, D., 215 Levin, V. A., 67 Muller, K. E., 333 Rinkevitch, D., 329
Jiang, G. L., 459 Levin, W., 849 Munzenrider, J. E., 439 Ritenour, E. R., 345
Johns, G. C., 709 Leybovich, L. B., 105 Murray, K., 193 Roach III, M., 299
Jose, B., 657 Lhomme, C., 419 Roberson, P. L., 629
Lindberg, R. D., 657 Roe, C. A., 333
Nagorney, D. M., 647
Kagami, Y., 29 Lindquist, C., 315 Roelstraete, A., 517
Narayan, K., 235
Kagan, A. R., 563 Ling, C. C., 161 Romestaing, P., 513
Narimatsu, N., 29
Kakehi, M., 491, 757 Linskey, M. E., 227 Rosenberger, F. U., 709
Nedzi, L. A., 859
Kao, G. D., 131 Liu, F. F., 849 Rosenblum, N., 885
Neilson, D. F., 193
Karlsson, B., 315 Loeffler, J. S., 557, 859 Rosenman, J. G., 123, 333
Nelson, J. S., 193
Karram, T., 329 LoSasso, T., 161 Rosner, G., 269
Nerlinger, R. E., 87
Karrison, T., 359 Low, N., 359 Ross, B. D., 95
Newcombe, D. J., 849
Kasper, M. E., 689 Lubin, R., 3 Ross, G. Y., 67
Niemierko, A., 135
Kaude, J. V., 425 Lukka, H., 805 Roszinski, S., 465
Niroomand-Rad, A., 745
Keane, T. J., 613 Lunsford, L. D., 227 Roy, J., 661
Nishio, M., 29
Kelsen, D. P., 821 Lyons, J. C., 95 Rubin, P., 1, 159, 389, 577, 763
Noone, B., 677
Kemeny, N., 821 Rubin, S., 359
Kendall, L. E., 251 Macdonald, D. R., 877 Ruifrok, A. C. C., 926
O’Gorman-Hughes, D., 431
Khil, M. S., 61 Mack, C. F., 801 Ryu, S., 61
Ohara, K., 49
Khoo, R., 791 Mack, Y., 619
Okunieff, P., 243
Kihlstrém, L., 315 MacKenzie, R., 613 Sack, H., 259
Oleson, J. R., 289, 841
Kim, J. H., 61 Mackie, R., 309 Saito, A., 29
Oouchi, A., 29
Kim, S. H., 61 Madoc-Jones, H., 758 Saleh, E. M., 683
O’Sullivan, B., 613
Kinsella, T. J., 309, 703 Mahe, M., 513 Saltz, L., 821
Kinzie, J. J., 339 Maire, J.-P., 907 Samulski, T. V., 289, 841
Kitagawa, T., 49 Malaise, E.-P., 405 Padfield, G., 283 Sanbe, S., 29
Klein, E. E., 541 Mameghan, H., 431 Pajak, T. F., 391 Sarkar, A., 251
Kleineidam, M., 277 Mameghan, J., 431 Paliwal, B. R., 525 Sarrazion, D., 419
Kligerman, M. M., 171 Mancuso, A. A., 683, 689 Panzarella, T., 623 Sathyanarayana, J. R., 805
Klitzman, B., 269, 481 Marcus, S., 399 Pardo, F., 243 Sato, S., 499
Kobeissi, B., 895 Markiewicz, W., 329 Paris, K. J., 657 Saw, C. B., 551
Kodym, R., 829 Marquis, I., 513 Parsons, J. T., 605, 619, 683, 689 Scalliet, P., 405
Kolker, J., 359 Marsden, D. S., 345 Patil, A. A., 325 Schiller, F., 277
Kooy, H. M., 859 Marsh, D. L., 299 Pavlicek, W., 345 Schoenfeld, A. H., 345
Kragelj, B., 777 Martenson, J. A., 647 Payne, D., 613 Schold Jr., S. C., 877
Krall, J., 783 Martinez, A., 647 Perez, C. A., 399, 733, 895 Schultheiss, T. E., 459
Kramar, A., 405 Marton, L. J., 251 Petereit, D., 309 Schultz, D. J., 885
Kubota, N., 491, 499, 757 Martz, K., 209, 391, 783 Peters, L. J., 147, 459 Schwartz, G., 821
Kubsad, S., 309 Maruhashi, A., 49 Phillips, T. L., 67, 209 Scott, C., 193
Kuhn, J. A., 473 Matsumoto, S., 35 Pickett, B., 299 Secomb, T. W., 481
Kumar, P. P., 325 Matthews, J. W., 709 Pierga, J.-Y., 871 Sentenac, I., 513
Kummermentr, J., 154 Matthews, J., 599 Pignon, J. P., 3, 153 Sexton, M., 413
Kurtts, T. A., 801 Matzner, M. B., 801 Pizer, S. M., 333 Shah, J. P., 17
Kurup, R. G., 105 Maunoury, C., 871 Plume, C. A., 835 Sham, J. S. T., 505
Kuske, R. R., 541 McCaul, G. F., 325 Podgorsak, M. B., 525 Sherar, M. D., 849
Kutchers, G. J., 161 McDermott, M. W., 67 Pontvert, D., 9 Shibuya, H., 35
McEwan, A. J. B., 805 Porter, A. T., 783, 805, 835 Shimn, D. S., 801
Lagarde, P., 113 McGowan, D. G., 805 Pothmann, B., 881 Ship, J. A., 41
Lally, B., 181 Mcllrath, D. C., 647 Poulter, C. A., 399 Shipley, W. U., 153
Lambin, P., 405 McLean, M., 623 Powe, J. E., 805 Showel, J., 929
Lanciano, R. M., 391, 885 Mehta, M. P., 309, 703 Powlis, W. D., 171, 193 Shrivastava, S. K., 926
Langevin, J., 791 Mendenhall, N. P., 425 Price, R. E., 459 Shulman, L. N., 765
Larson, D. A., 557 Mendenhall, W. M., 605, 619, 683, Pritchard, D. J., 647 Silver, B., 765
Lave, C., 9 689 Procter, H. D., 895 Sim, F., 647
XII
Sindelar, W. F., 445 Suit, H., 243 Trouette, R., 907 Waterman, F. M., 87
Slevin, N. J., 17, 379 Supe, S. J., 926 Tsuji, H., 49 Wei, W. I., 505
Smith, A. R., 171, 181 Suzuki, S., 35 Tsujii, H., 49 Weichselbaum, R. R., 359
Smith, B. D., 895 Svensson, G. K., 79, 859 Tupchong, L., 87 Weinstein, A. S., 193
Smith, J. G., 235 Swift, P. S., 209 Turski, P., 309 Weitzmen, S., 215
Smith, M. T., 67 Syh, H.-W., 325 Werner-Wasik, M., 758
Smith, P. D., 445 Symon, J. R., 123 Uematsu, M., 765 Werts, E. D., 925
Socie, G., 3, 871 Szigety, S. K., 695 Unie, M. M., 353, 439 Wesolowski, C., 805
Solin, L. J., 885 Urtasun, R., 243, 695 Whitelocke, R. A. F., 815
Sombeck, M. D., 425 Tabor, P., 881 Whittington, R., 131
Somekawa, Y., 29 Tada, J., 49, 499 Valdez, I. H., 41 Wieand, H. S., 647
Song, C. W., 95 Taghian, A., 243 Valette, H., 981 Williams, L. E., 473
Soubeyran, P., 113 Takada, Y., 49 van den Aardweg, A. J., 927 Williamson, J. F., 733
Spanos Jr., W. J., 399, 657, 757 Takagi, M., 35 Van den Heuvel, F., 517 Wiseberg, J., 821
Speiser, B. L., 579, 589, 925 Takeda, M., 35 van der Kogel, A. J., 926 Withers, H. R., 151
Spratling, L., 579, 589, 925 Tatera, B. S., 299 Vasanthan, S., 23 Wong, A., 791
Stanonik, M., 777 Tatuzaki, H., 49 Vedula, R., 721 Wong, C. S., 669
Steinberg, S. M., 445 Taylor, J. M. G., 151 Venner, P., 783 Wong, J. Y. C., 473
Steiner, L., 315 Taylor, W. B., 849 Verellen, D., 517 Worotniuk, V., 599
Steinfeld, A. D., 399 Tchernia, G., 871 Viebahn, M., 379 Wu, A., 551
Stephens, L. C., 459 Teicher, B. A., 79 Vijayakumar, S., 359 Wu, P. M., 505
Steplewski, Z., 629 Ten Haken, R. K., 629 Villari, F., 171 Wiirschmidt, F., 73
Stern, H., 669 Tester, W., 783 Visser, A. G., 529
Stevenson, D. S., 123 Thames, H. D., 9 Viswanathan, P. S., 926
Yakemchuk, V. N., 805
Stitt, J. A., 525 Thomadsen, B. R., 525 Volk, T., 465
Yang, C., 235
Stoll, D., 113 Thomas, G. M., 805
Yardley, J., 805
Storme, G., 517 Thomas, G., 445 Wallner, K., 661
Stringer, S. P., 619, 689 Thon, L., 517 Wanek, P. M., 473
Strong, E. W., 17 Tochner, Z., 445 Wara, W., 209 Zakotnik, B., 777
Strother, C., 309 Torres, G. M., 425 Warde, P., 623 Zapotowski, K. A., 299
Stroud, D. N., 339 Traissac, L., 113 Warrington, A. P., 815 Zelefsky, M. J., 17
Stuschke, M., 259 Trott, K.-R., 154 Wasserman, T. H., 895 Zouranjian, P. S., 79
XIV
SUBJECT INDEX
Volume 25, 1993
A Lung, 703 Constrictive pericarditis, 329
Muscle-invasive bladder, 777 Control
Non-small cell lung, 599 Local, 3, 113, 513
Abdominal malignancy, 445 Ovarian, 445 Quality, 333
Absorber, 849 PC-3 cells, 283 Tumor, 79
Accelerated fractionation, 399 Prostate, 359, 805 Cost accounting, 895
Accuracy, 117 Rectal, 669, 791, 821 Cost analysis for radiation therapy, 895
Acoustic tumor, 227 Recurrent breast, 79 Cranial nerve, 227
Acute toxicity, 359 Therapy, 629 Cross-section variable, 105
Adjuvant therapy, 821 Tongue, 29 CT scan-based analysis, 877
Amersham system, 721 Treatment of prostate, 299 Cumulative minutes, 841
Amilorade, 95 Uterine cervix, 733
Amputation, 431 Cancer cells D
Analysis DU-145, 283
CT scan-based, 877 PC-3, 283
Dose volume histogram, 353 Carcinoma(s) Deep-seated tumors, 49
Radiation therapy cost, 895 Cervix, 405 DIDS, 95
Angiography Head and neck, 9 Difluoromethylornithine, 639
Magnetic resonance, 309 Larynx/hypopharynx, 613 Digital enhancement, 333
Stereotactic, 309 Nasopharyngeal, 505 Disease
Angioma, 689 Oral tongue, 513 Hodgkin’s, 425, 771, 871
Antibody(ies), 629 Penis, 623 Radiation induced, 871
'311odine monoclonal, 629 Prostatic, 661 Distributed-memory, 709
Monoclonal, 629 Squamous cell, 17, 619 Dose, 23
Radiolabeled, 629 Uterine cervix, 3 Distribution, 49, 499
Yttrium monoclonal, 629 Vagina, 413 Genetically significant, 745
Arteriovenous malformation(s), 309, 353, 381 Cataract, 815 Gonadal, 745
Astrocytoma CDDP, 491 Homogeneity, 551
Glioblastoma multiforme (GBM) and an- Celiac axis, 131 Inhomogeneity, 339
aplastic, 193 Cell(s) Thermal, 87
Malignant (high grade), 193 DU-145 cancer, 283 To ovaries and testes, 745
Autoradiography, 881 Human carcinoma, 61 Dose-rate, 277
Quantitative, 629 Human glioma, 251 Dose-response, 135
Melanoma, 491 Relationship, 149
PC-3 cancer, 283 Dose-time-control relationships, 9
B
Squamous cancer, 391 Dose-volume histogram, 733
Cell-cycle-effects, 277 Analysis, 353
Central nervous system (CNS), 67, 695 Dosimetry, 551, 629, 881
Beam’s eye view, 359
Cerebral radiation injury, 315 Interface, 541
Bladder cancer, 783
Cervical nodes, 9 Thermal, 289, 841
Muscle-invasive, 777
Cervix carcinoma, 405 DU-145 cancer cells, 283
Bladder preservation, 777
Cesium, 29
Bolus, 849
Chemotherapy, 79, 419, 431, 465, 791
Bone-marrow-stromal-cells, 829 E
Children, 215
Brachytherapy, 29, 277, 405, 505, 551, 661,
Chondrosarcomas, 439
733, 835
Chordomas, 439
Endobronchial, 579, 589, 703 Education in radiation oncology, 345
Cisplatin, 73, 79, 783
High dose rate, 525, 579 Effects
Clinical trials, 289
Iodine-125 stereotactic, 325 Late, 431
Colon cancer, 473, 629
Brain, 381, 695 Radiation, 329, 541, 695, 907
Combined modality, 783
Metastases, 209 Endobronchial brachytherapy, 579, 589, 703
Treatment, 73, 771, 777
Stem tumors, 235 Error, 117
Combined treatment, 113
Tumor therapy, 639 Ethmoidal cancer, 113
Comparative planning, 353
Breast cancer, 529, 541, 765 Ewing’s sarcoma, 431
Complication probability, 135
Recurrent, 79 Exponential growth, 835
Normal tissue, 135
Bulky mediastinal mass, 771
Complications, 79, 431, 885
Late, 405 F
C Thermal, 841
Computed
Tomography, 209, 661 Field(s)
Cancer, 41 X-ray, 689 Hodgkin’s 745
Bladder, 783 Computer-based model, 895 Shaping, 181
Breast, 529, 541, 765 Computers, 123 5 fluorouracil, 613
Colon, 473, 629 Conformal Flux, 269
DU-145 cells, 283 Radiation therapy, 171 Fractionated irradiation, 73, 251
Ethmoidal, 113 Radiotherapy, 161 Fractionation, 23, 381
Head and neck, 3 Therapy, 359, 849 Accelerated, 399
Human prostate, 283 Treatment, 181 Rapid hyper, 657
XV
e L N
Gamma knife, 227 Laparotomy, 425 Nasopharyngeal
Gastrointestinal, 399 Laryngeal neoplasms, 149, 605, 683 Carcinoma, 505
Malignancies, 131 Laryngectomy, 683 Neoplasms, 689
Genetically significant dose, 745 Larynx, 23 Nasopharynx, 161
Glioblastoma multiforme (GBM) and ana- Laser, 445 Neoplasm(s)
plastic astrocytoma, 193 Late Head and neck, 619
Glioma(s) Complications, 405 Laryngeal, 149, 605, 683
Malignant, 193, 243, 877 Morbidity, 23 Nasopharyngeal, 689
Optic, 215 Late effects, 431 Staging, 425, 683
Gonadal dose, 745 Of radiation, 815 Non-small cell lung cancer, 599
Gynecologic, 399 Latent period, 459 Normal tissue, 135
Linear accelerator, 117 Complication probability, 135
Linear-quadratic, 381 Toxicity, 73
Lipid peroxidation, 67 Nuclear magnetic resonance (NMR), 695
H Local
Control, 3, 113, 439, 513
Excision, 669 O
Head and neck
Locally advanced lesions, 647
Cancer, 3
Low-dose-rate, 405, 835
Carcinomas, 9 Obesity, 605
Irradiation, 325
-Malignancies, 657 Oncology programs in radiation, 345
Lung cancer, 703
Neoplasms, 619 106-Ru-thenium eye plaques, 277
Non-small cell, 599
Heavy charged particles, 49 On-line portal imaging, 517, 529
Lymph node excision, 619
Hematocrit, 269 Ophthalmic plaque, 881
Lymphatic metastasis, 619
Hematoporphyrin derivative, 445 Optic glioma, 215
Lymphography, 425
High dose rate brachytherapy, 525, 579 Oral, 41
Hip prosthesis, 339 Tongue carcinoma, 513
Hodgkin’s Osseous metastases, 805
Disease, 425, 771, 871 M Ovarian
Fields, 745 Cancer, 445
Human Transposition, 419
Magnetic resonance
Carcinoma cells, 61 Overall survival, 3
Angiography, 309
Glioma cells, 251 Oxygenation, 481
Imaging (MRI), 315, 689
Prostate cancer, 283
Malignancy(ies), 381
Xenografts, 259
Abdominal, 445 P
Hyperfractionated radiation therapy, 193 Chaeniotisinsl. 131
Hyperglycemia, 465 Head and neck, 657
Hyperthermia, 79, 87, 289, 491, 841, 849 : :
Palliation, 399, 801
Interstitial, 105 Malignant ;
Sinaia : Astrocytoma (high grade), 193 Response, 657
yp Glioma(s), 193, 243, 877 Parallel processing, 709
Intratumor, 283 :
Radiobiological, 481 Melanoma, 35, 87 Patient
: Tumors, 465 Exclusion, 9
Mastectomy, 765 Positioning, 529
Mathematical model, 481 PC-3 cancer cells, 283
Melanoma(s) Pelvic
Cells, 491 Irradiation, 885
Malignant, 35, 87 Radiotherapy, 517
ICRU report 38, 733 Meningioma, 325 Penis carcinoma, 623
Interface dosimetry, 541 Metastasis(es) Pentoxifylline, 61
Interphase-chromosome-breaks, 829 Brain, 209 Penumbra, 181
Interstitial Lymphatic, 619 Pericardiectomy, 329
Hyperthermia, 105 Osseous, 805 Peripheral nerve injury, 227
Implant(s), 505, 551 MgRaEc-hr, 733 Persistent, 505
Radiotherapy, 29 Microwave, 849 pH, 465
Intracavitary irradiation, 733 Antenna, 105 Phase III trial, 405
Intracellular pH, 95 Misonidazole, 209 Photosensitizer, 445
Intraoperative irradiation, 647 Mitomycin C, 613 Physics training in radiation, 345
Intraoral therapy, 35 Model, 907 Pituitary adenoma, 677
Intratumor hypoxia, 283 Computer-based, 895 Planning
Intrinsic, 3 Mathematical, 481 Comparative, 353
Radiosensitivity, 243 Modeling, 135 Treatment, 135
Iodine-125, 661 Mold therapy, 35 Platinum complexes, 491
Seeds, 881 Monoclonal antibodies, 629 pO>, 465
Stereotactic brachytheray, 325 '3'Todine, 629 Point A dosimetry, 721
'3!Todine monoclonal antibodies, 629 Yttrium, 629 Portal film, 333
Iridium-192 implantation, 513 Multicellular spheroids, 251 Positive margins, 17
Irradiation Multileaf Postoperative radiation, 17
Fractionated, 73, 251 Collimation, 161 Therapy, 765
Intracavitary, 733 Collimator (MLC), 171, 181, 849 Predictive assays, 3, 243
Intraoperative, 647 Multiple myeloma, 801 Premature-chromosome-condensation, 829
Low-dose-rate, 325 Multivariate analysis, 605 Preoperative, 791
Pelvic, 885 Muscle phantom, 105 Prognosis, 605
Sarcoma, 647 Muscle-invasive bladder cancer, 777 Prostate, 161
Isocenter, 117 Myelopathy, 459 Simulation, 299
XVI
Prostate cancer, 359, 805 Reimbursement, 895 TLD measurements, 339
Human, 283 Reirradiation, 79, 459 TMR algorithm, 339
Treatment, 299 Reoxygenation, 277 Tocopherol, 67
Prostatic carcinoma, 661 Repair, 277, 829 Tolerance, 459
Prosthesis(es), 541 Repopulation, 277 Tomography, 425, 689
Hip, 339 Resectability, 791 Computed, 209, 661
Proton(s), 353 Resection, 215 X-ray computed, 683
Therapy, 49, 439 Reseeding to the nodes, 9 Tongue cancer, 29
Putrescine, 639 Response Total dose, 277
Palliation, 657 Toxicity, 791
Q Tumor, 73 Acute, 359
Results, 623 Normal tissue, 73
Rhabdomyosarcoma, 73 Transputer, 709
Quality assurance, 299 RTOG, 209 Treatment planning, 131, 135, 849, 907
In radiotherapy, 529 Radiation therapy, 339
Quality control, 333 S Three-dimensional, 123, 171, 439, 709
Quantitative autoradiography, 629 Treatment
Combined, 113
R Saliva, 41, Combined modality, 73, 771, 777
Sarcoma(s, 445) Conformal, 181
Ewing’s, 431 Prostate cancer, 299
Radiation, 87, 149 Irradiation, 647 Radiation, 3, 215
Bronchitis, 589 Soft tissue, 647 Time, 391
Cerebral injury, 315 Sclerosing, 689 Verification, 529
Effects, 329, 541, 695, 907 Sensitivity to radiation, 283 Trial(s)
Induced heart disease, 871 SF,, 243 Clinical, 289
Late effects of, 815 Side-effects, 359 Phase III, 405
Necrosis, 513 Small intestine, 885 Tritium, 639
Physics training, 345 Soft tissue sarcomas, 647 Tumor(s), 277
Postoperative, 17 Spheroid(s), 491 Acoustic, 227
Radical, 405 Multicellular, 251 Brain stem, 235
Sensitivity, 283 Squamous cell Control, 79
Techniques, 299 Cancer, 391 Deep-seated, 49
Treatment, 3, 215 Carcinoma, 17, 619 Malignant, 465
Radiation injury(ies), 67, 329 Staging, 113 Microvasculature, 269
Cerebral, 315 Neoplasm, 425, 683 Response, 73
Radiation oncology Stereotactic, 381, 709
Education in, 345 Angiography, 309 U
Programs, 345 lodine-125, brachytherapy, 325
Radiation therapy, 41, 131, 669, 695, 703, Radiosurgery, 227, 849
791, 815, 821, 841, 877 Strontium-89, 805 Ultrahigh energy neutron, 499
Conformal, 171 Surveillance, 215 Upper jaw, 35
Cost analysis, 895 Survival, 431 Urethrograms, 299
Hyperfractionated, 193 Overall, 3 Uterine cervix, 391
Postoperative, 765 Cancer, 733
Treatment planning, 339 T Carcinoma, 3
Radical radiation, 405 Uterine configuration, 721
Radiobiological hypoxia, 48 1
Radiography, 525
Too, 841 V
Radioimmunoglobulin therapy, 629 TCDs0, 259
Radioimmunotherapy, 473, 629 Techniques, 359
Radiolabeled antibodies, 629 Radiation, 299
Vaginal cylinders, 525
Radioresponse, 61 Tetracyclines, 329
Variable cross-section, 105
Radiosensitivity, 3 Thallium scintigraphy, 871
Vestibular schwannoma, 227
Intrinsic, 243 Therapy
Radiosurgery, 117, 309, 315, 381 Adjuvant, 821
Stereotactic, 227, 849 Brain tumor, 639 WwW
Radiotherapy, 9, 35, 49, 79, 149, 235, 419, Cancer, 629
431, 541, 599, 605, 613, 619, 623, Conformal, 359, 849
677, 683, 689, 783, 801, 805 Intraoral, 35 Waveguide, 849
Conformal, 161 Mold, 35
Interstitial, 29 Proton, 49, 439
X
Pelvic, 517 Radiation, 41, 131, 669, 695, 703, 791,
Quality assurance in, 529 815, 821, 841, 877
Rapid hyper fractionation, 657 Radioimmunoglobulin, 629
X-ray computed, 425, 689
Rat spinal cord, 67 Thermal
Tomography, 683
RBE, 499, 835 Complications, 841
Real-time, 709 Dose, 87
Reconstruction, 541 Dosimetry, 289, 841 Y
Rectal cancer, 669, 791, 821 Parameters, 841
Recurrences, 439 Thermosensitization, 95
Recurrent, 505 Three-dimensional WY 473
Breast cancer, 79 Treatment planning, 123, 171, 439, 709 69Vb 835
Regrowth delay, 259 Displays, 123 Yttrium monoclonal antibodies, 629
XVII